Silenced Fc variants engineered with LALA, LALA-PG, EN, N297Q, and related mutations to reduce Fc-mediated effector functions.
Compare seven Fc-engineered antibody expression vectors to select an appropriate effector-attenuated variant for your research.
| Catalog No. | Variant | Engineering Mechanism | Selection Guidance |
|---|---|---|---|
| AFV-04 | Human IgG1 (EN) | Lower-hinge and CH2 engineering | Broad Fc-effector attenuation studies |
| AFV-13 | Human IgG1 (LALA-PG) | L234A / L235A / P329G | Strong Fc-effector attenuation |
| AFV-12 | Human IgG1 (LALA) | L234A / L235A | Established Fc-silencing benchmark |
| AFV-05 | Human IgG1 (N297Q) | N297Q; removal of Fc N-glycosylation site | Aglycosylated Fc comparison |
| AFV-16 | Human IgG1 (ΔG236) | Deletion of G236 | Alternative FcγR-interaction engineering |
| AFV-14 | Mouse IgG2a (LALA-PG) | L234A / L235A / P329G | Mouse IgG2a effector attenuation |
| AFV-15 | Mouse IgG2a (N297Q) | N297Q; removal of Fc N-glycosylation site | Mouse IgG2a aglycosylation studies |
Functional attenuation depends on antibody sequence, Fc receptor, assay system, and experimental conditions. Confirm FcγR binding, C1q binding, and effector activity as appropriate.
Showing all 7 results